ES2571253T3 - Derivados de fenil pirrol aminoguanidina - Google Patents

Derivados de fenil pirrol aminoguanidina

Info

Publication number
ES2571253T3
ES2571253T3 ES11164583T ES11164583T ES2571253T3 ES 2571253 T3 ES2571253 T3 ES 2571253T3 ES 11164583 T ES11164583 T ES 11164583T ES 11164583 T ES11164583 T ES 11164583T ES 2571253 T3 ES2571253 T3 ES 2571253T3
Authority
ES
Spain
Prior art keywords
phenyl pyrrole
aminoguanidine derivatives
pyrrole aminoguanidine
derivatives
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11164583T
Other languages
English (en)
Inventor
Arne Boman
Thomas Engelbrecht Norkild Jonassen
Torbjörn Lundstedt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synact Pharma ApS
Original Assignee
Synact Pharma ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synact Pharma ApS filed Critical Synact Pharma ApS
Application granted granted Critical
Publication of ES2571253T3 publication Critical patent/ES2571253T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/42—Nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Un compuesto de fórmula general (I)**Fórmula** incluyendo formas tautoméricas del mismo, en la que n es 1, 2 o 3; cada R1, R2, R3, R4 10 y R5 se selecciona independientemente entre el grupo que consiste en hidrógeno, alquilo C1-6 opcionalmente sustituido, cicloalquilo C3-6 opcionalmente sustituido, alquenilo C2-6 opcionalmente sustituido, alcadienilo C4-6 opcionalmente sustituido, alquinilo C2-6 opcionalmente sustituido, hidroxi, alcoxi C1-6 opcionalmente sustituido, alqueniloxi C2-6 opcionalmente sustituido, carboxi, alcoxicarbonilo C1-6 opcionalmente sustituido, alquilcarbonilo C1-6 opcionalmente sustituido, formilo, alquilsulfonilamino C1-6, arilo opcionalmente sustituido, ariloxicarbonilo opcionalmente sustituido, ariloxi opcionalmente sustituido, arilcarbonilo opcionalmente sustituido, arilamino opcionalmente sustituido, arilsulfonilamino, heteroarilo opcionalmente sustituido, heteroariloxicarbonilo opcionalmente sustituido, heteroariloxi opcionalmente sustituido, heteroarilcarbonilo opcionalmente sustituido, heteroarilamino opcionalmente sustituido, heteroarilsulfonilamino, heterociclilo opcionalmente sustituido, heterocicliloxicarbonilo opcionalmente sustituido, heterocicliloxi opcionalmente sustituido, heterociclilcarbonilo opcionalmente sustituido, heterociclilamino opcionalmente sustituido, heterociclilsulfonilamino, amino, mono- y di(alquil C1-6)amino, carbamoílo, mono- y di(alquil C1-6)aminocarbonilo, amino-alquil C1-6-aminocarbonilo, mono- y di(alquil C1-6)amino-alquil C1-6-aminocarbonilo, alquilcarbonilamino C1-6, amino-alquilcarbonilamino C1-6, mono- y di(alquil C1-6)amino-alquil C1-6-carbonilamino, ciano, guanidino, carbamido, alcanoiloxi C1-6, alquil C1-6-sulfonilo, alquilsulfinilo C1-6, alquilsulfoniloxi C1-6, aminosulfonilo, mono- y di(alquil C1-6)aminosulfonilo, nitro, alquiltio C1-6 opcionalmente sustituido y halógeno, en los que cualquier alquilo C1-6 unido a nitrógeno está opcionalmente sustituido con hidroxi, alcoxi C1-6, alqueniloxi C2-6, amino, mono- y di(alquil C1-6)amino, carboxi, alquilcarbonilamino C1-6, halógeno, alquiltio C1-6, alquil C1-6-sulfonilamino o guanidino; cada R6 y R7 se selecciona independientemente entre el grupo que consiste en hidrógeno, alquilo C1-6 opcionalmente sustituido, alquenilo C2-6 opcionalmente sustituido, alcadienilo C4-6 opcionalmente sustituido, alquinilo C2-6 opcionalmente sustituido, alcoxicarbonilo C1-6 opcionalmente sustituido, alquilcarbonilo C1-6 opcionalmente sustituido, arilo opcionalmente sustituido, ariloxicarbonilo opcionalmente sustituido, arilcarbonilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heteroariloxicarbonilo opcionalmente sustituido, heteroarilcarbonilo opcionalmente sustituido, aminocarbonilo, mono- y di(alquil C1-6)aminocarbonilo, amino-alquil C1-6-aminocarbonilo y mono- y di(alquil C1-6)amino-alquil C1-6-aminocarbonilo; o R6 y R7 en conjunto pueden formar un anillo que contiene nitrógeno de cinco o seis miembros; o una sal farmacéuticamente aceptable del mismo.
ES11164583T 2006-06-09 2007-06-11 Derivados de fenil pirrol aminoguanidina Active ES2571253T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200600780 2006-06-09

Publications (1)

Publication Number Publication Date
ES2571253T3 true ES2571253T3 (es) 2016-05-24

Family

ID=58709169

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11164583T Active ES2571253T3 (es) 2006-06-09 2007-06-11 Derivados de fenil pirrol aminoguanidina

Country Status (19)

Country Link
US (1) US8058306B2 (es)
EP (2) EP2348016B1 (es)
JP (1) JP5444523B2 (es)
CN (1) CN101466669B (es)
AT (1) ATE508111T1 (es)
AU (1) AU2007255366B2 (es)
CA (1) CA2688485C (es)
CY (1) CY1117851T1 (es)
DE (1) DE602007014363D1 (es)
DK (1) DK2348016T3 (es)
ES (1) ES2571253T3 (es)
HK (1) HK1160136A1 (es)
HU (1) HUE029016T2 (es)
MX (1) MX2008015454A (es)
NZ (1) NZ573457A (es)
PL (1) PL2348016T3 (es)
SI (1) SI2348016T1 (es)
WO (1) WO2007141343A1 (es)
ZA (1) ZA200810347B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009071101A1 (en) * 2007-12-07 2009-06-11 Action Pharma A/S N-modified aminoguanidine derivatives
WO2009074157A1 (en) * 2007-12-13 2009-06-18 Action Pharma A/S Fully-modified phenyl pyrrole aminoguanidines
UA99555C2 (en) 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
JP7124130B2 (ja) * 2018-06-22 2022-08-23 シナクト ファーマ エーピーエス 蛋白尿の治療
AU2020273479A1 (en) 2019-05-10 2021-12-23 Synact Pharma Aps Combination treatment of arthritic disease
JP2023521614A (ja) * 2020-03-31 2023-05-25 シナクト ファーマ エーピーエス 症候性ウイルス疾患の処置
KR20240024177A (ko) * 2021-06-21 2024-02-23 신액트 파마 에이피에스 페닐 피롤 아미노구아니딘의 염 및 페닐 피롤 아미노구아니디늄 염의 다형체
WO2023218048A1 (en) 2022-05-12 2023-11-16 Synact Pharma Aps Resomelagon and its derivatives for the treatment of cardiovascular disease, hypertension and atherosclerosis
WO2024133643A1 (en) * 2022-12-21 2024-06-27 Synact Pharma Aps Polymorph of phenyl pyrrole hydrazine carboximidamide compound

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604348D0 (sv) 1996-11-26 1996-11-26 Wapharm Ab Användning av hydroxyguanidiner
WO1999021571A1 (en) 1997-10-27 1999-05-06 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same
EP1076649A4 (en) 1998-04-28 2010-06-02 Trega Biosciences Inc ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE
AU742425B2 (en) 1998-06-11 2002-01-03 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
ES2304345T3 (es) 1999-03-29 2008-10-16 THE PROCTER & GAMBLE COMPANY Ligandos del receptor de melanocortina.
CA2377369A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
AU6605800A (en) 1999-07-16 2001-02-05 Trega Biosciences, Inc. Melanocortin receptor-3 ligands to treat sexual dysfunction
AU2001228681A1 (en) 2000-01-28 2001-08-07 Melacure Therapeutics Ab Novel aromatic amines and amides acting on the melanocortin receptors
GB0002059D0 (en) 2000-01-28 2000-03-22 Melacure Therapeutics Ab Novel aromatic amines
IL150898A0 (en) 2000-01-28 2003-02-12 Melacure Therapeutics Ab Novel melanocortin receptor agonists and antagonists
GB0019357D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
GB0019359D0 (en) * 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
DZ3415A1 (fr) 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
GB0119172D0 (en) 2001-08-06 2001-09-26 Melacure Therapeutics Ab Phenyl pyrrole derivatives

Also Published As

Publication number Publication date
CN101466669A (zh) 2009-06-24
HUE029016T2 (en) 2017-02-28
EP2035373A1 (en) 2009-03-18
ZA200810347B (en) 2010-05-26
DE602007014363D1 (de) 2011-06-16
CA2688485A1 (en) 2007-12-13
US20110082183A1 (en) 2011-04-07
CY1117851T1 (el) 2017-05-17
EP2348016B1 (en) 2016-02-17
DK2348016T3 (en) 2016-05-30
JP5444523B2 (ja) 2014-03-19
CN101466669B (zh) 2011-11-30
PL2348016T3 (pl) 2016-09-30
US8058306B2 (en) 2011-11-15
NZ573457A (en) 2011-06-30
EP2348016A1 (en) 2011-07-27
JP2009539809A (ja) 2009-11-19
WO2007141343A1 (en) 2007-12-13
ATE508111T1 (de) 2011-05-15
SI2348016T1 (sl) 2016-10-28
CA2688485C (en) 2016-01-05
AU2007255366B2 (en) 2013-07-18
EP2035373B1 (en) 2011-05-04
MX2008015454A (es) 2009-01-30
HK1160136A1 (zh) 2012-08-10
AU2007255366A1 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
CY1117851T1 (el) Παραγωγα φαινυλ-πυρρολ-αμινογουανιδινης
CY1113029T1 (el) Παραγωγα αζαδικυκλο [3.1.0] εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
ATE402697T1 (de) 1,3,5-trisubstituierte 4,5-dihydro-1h-pyrazol- derivative mit cb1-antagonistischer aktivität
TN2009000199A1 (en) Heteromonocyclic compound and use thereof
BRPI0716598A2 (pt) Derivados de (hetero) arilsulfonamida de n-biarila úteis no tratamento de doenças medidas por interações de linfócitos
EA200802213A1 (ru) Способы лечения заболеваний крови
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
BR0312729A (pt) Novos derivados de indol-3-enxofre
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
EA201000050A1 (ru) Замещенные бициклолактамные соединения
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
WO2007142905A3 (en) 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands
NO20082096L (no) Azaindol-2-karboksamidderivativer
TW200714603A (en) Acylaminobicyclic heteroaromatic compounds and uses thereof
EA200801596A1 (ru) Новые 11-бета-гидроксиандроста-4-ен-3-оны
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
MX2009012376A (es) Derivados de pirimidona sustituidos con heteroarilamida para el tratamiento de enfermedades neurodegenerativas.
DE602007006328D1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
DE602005007765D1 (de) Neue indol- oder benzimidazol-derivate
ATE492534T1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
TW200740766A (en) Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands
MX2008002158A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6.
ATE456570T1 (de) Isothiazolopyridin-3-ylenamine zur bekämpfung tierischer schädlinge
TW200745053A (en) 9-Aminocarbonylsubstituted derivatives of glycylcyclines